SynthesisEye (London, England)2026
Anti-vascular endothelial growth factor for the management of peripapillary choroidal neovascular membrane.
Synthesis in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the evidence on the use of anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of peripapillary choroidal neovascular membrane (pCNVM).
methodsMedline, Embase, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched between January 2000 and December 2024 for relevant articles that used anti-VEGF therapy to treat pCNVM of any origin. This review followed PRISMA guidelines and was prospectively registered (PROSPERO registration number CRD42024551949).
resultsTen studies reporting on 269 eyes were included. The most common treatment strategy was pro re nata (PRN), used in 8 studies. One study used a fixed interval regimen, and another used a loading phase followed by PRN. Across all studies, the average number of anti-VEGF injections was 7 per eye over a mean follow-up duration of 34 months (range: 3-44 months). Eight studies reported improvements in best corrected visual acuity (BCVA) at final follow-up following treatment. The mean logarithm of the minimum angle of resolution (logMAR) change was 0.092, or approximately one line Snellen improvement. Two studies reported on macular thickness, and one reported on choroidal thickness after treatment, all of which noted decreased thickness at final follow-up. No significant complications were reported.
conclusionsFor patients with pCNVM of various aetiologies, anti-VEGF injections using any treatment strategy, including conservative management with a PRN approach, seem to be a safe and effective therapy associated with improved visual acuity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.